Indian pharma major Cipla Ltd said it has acquired an anti-infective product Elores from Venus Remedies Ltd to boost its presence in country’s branded critical care segment.
Umang Vohra, managing director and global chief executive officer at Cipla, said in a statement that the acquisition of Elores underscores the company's commitment to its anti-microbial portfolio. He did not disclose the financial details of the transaction.
Elores, a novel drug combination that is meant for the treatment of life threatening infections, helps preserve the efficacy of the antibiotic using appropriate Antibiotic Resistance Breakers (ARBs). The product was launched in India in 2013 after approval from the Drug Controller General of India.
Saransh Chaudhary, chief executive officer at Venus Medicine Research Centre, said that while the company has sold Elores to Cipla, anti-microbial continues to be the core focus for the firm.
In a push to strengthen its anti-microbial portfolio, the Mumbai-based drugmaker also acquired another anti-infective product ZEMDRI™ from Achaogen Inc earlier in July.
Cipla deals this year
Earlier in July, Cipla formed a joint venture (JV) with Chinese firm Jiangsu Acebright Pharmaceutical Co. Ltd, as the Indian drugmaker seeks to make a fresh push into the Asian country.
The pharmaceuticals company also invested in new age digital companies this year. Cipla acquired a 30% stake in South Africa's Brandmed (Pty.) Ltd to increase its exposure to the connected healthcare segment in April.
Prior to this in February, Cipla bought a stake in health-tech startup Wellthy Therapeutics Pvt. Ltd as part of a deal where the companies agreed to offer a digital disease management platform to patients in the cardio-metabolic segment.
In the recently held VCCircle Healthcare Summit, Vohra said that pharmaceutical companies’ profit pools will likely move away from manufacturing to care as they re-imagine themselves as service providers and not just pill suppliers.